General Information of Drug (ID: DMF6WHC)

Drug Name
(1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol Drug Info
Synonyms
63006-93-9; (1,2,3,4-Tetrahydroisoquinolin-3-yl)methanol; 1,2,3,4-Tetrahydroisoquinoline-3-methanol; (1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol; 1,2,3,4-tetrahydroisoquinolin-3-ylmethanol; (S)-(-)-1,2,3,4-Tetrahydro-3-isoquinolinemethanol; 62928-94-3; CHEMBL60068; 1,2,3,4-tetrahydro-3-isoquinolinemethanol; 3-Isoquinolinemethanol, 1,2,3,4-tetrahydro-; 3-Hydroxymethyl-1,2,3,4-tetrahydroisoquinoline; F2147-1627; PubChem5794; AC1MWNWL; (S)-1,2,3,4-Tetrahydroisoquinolylmethan-3-ol; ACMC-209err; ChemDiv2_003241
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3752277
TTD Drug ID
DMF6WHC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [2]
Dihydroergocristine DM5SQ1G Alcohol dependence 6C40.2 Approved [3]
Brimonidine DMQLT4N Ocular hypertension 9C61.01 Approved [4]
Amosulalol DML8QSZ Hypertension BA00-BA04 Approved [5]
Amezinium DM6I2WQ Hypotension BA20-BA21 Approved [6]
Propylhexedrine DMTBW2O Obesity 5B81 Approved [7]
Tetrahydrozoline DMT57WC Ocular disease 1F00.1Z Approved [8]
Rilmenidine DM13PQW Hypertension BA00-BA04 Approved [9]
Xylometazoline DMKV32D Allergic rhinitis CA08.0 Phase 4 [10]
TNX-102 DMO1234 Fibromyalgia MG30.01 Phase 3 [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lofexidine DM1WXA6 Heroin and opiate withdrawal 6C43 Approved [12]
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [2]
Connexyn DMF29Q5 Attention deficit hyperactivity disorder 6A05.Z Approved [13]
Guanfacine DMPN5IH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [14]
A295 DM55GO2 Aggressive cancer 2A00-2F9Z IND submitted [15]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [16]
DSP-1200 DM4WSHG Depression 6A70-6A7Z Phase 1 [17]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [18]
NMI-870 DMU596F Sexual dysfunction HA00-HA01 Discontinued in Phase 2 [19]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [20]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [2]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [16]
AGN-199981 DMP5Y1A Neuropathic pain 8E43.0 Phase 2 [21]
INDORAMIN DMNSJFD Hypertension BA00-BA04 Withdrawn from market [22]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [18]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [20]
A-80426 DMBC3DG N. A. N. A. Terminated [23]
WB-4101 DMQU8B1 N. A. N. A. Terminated [24]
SK&F-104078 DMRADBU N. A. N. A. Terminated [22]
(+/-)-nantenine DM0L3GE Discovery agent N.A. Investigative [25]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor alpha-2A (ADRA2A) TTWG9A4 ADA2A_HUMAN Inhibitor [1]
Adrenergic receptor alpha-2B (ADRA2B) TTWM4TY ADA2B_HUMAN Inhibitor [1]
Adrenergic receptor alpha-2C (ADRA2C) TT2NUT5 ADA2C_HUMAN Inhibitor [1]

References

1 3,7-Disubstituted-1,2,3,4-tetrahydroisoquinolines display remarkable potency and selectivity as inhibitors of phenylethanolamine N-methyltransferas... J Med Chem. 1999 Jun 3;42(11):1982-90.
2 Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
3 Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
5 Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
6 Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
7 Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
8 Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
9 Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
10 Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
11 Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
12 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
13 alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
14 Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
15 Clinical pipeline report, company report or official report of Klus Pharma
16 A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
17 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
18 A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
19 Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
20 Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
21 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
22 Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
23 Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
24 alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
25 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.